tbuckley/cabot-search huggingface dataset:
Bevacizumab plus infusional 5-FU, leucovorin and irinotecan (FOLFIRI) for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study
Authors: H. Kwon, D. Lee, S. Kim, S. Y. Oh, H. J. Choi, K. Park, M. S. Roh, S. Kim, H. Kim
Journal: Journal of Clinical Oncology (2007)

14593 Background: The humanized monoclonal antibody bevacizumab inhibits angiogenesis, and improves survival when combined with chemotherapy for advanced colorectal cancer. The purpose of this trial is to evaluate the combination of bevacizumab with infusional 5-FU, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5- FU), leucovorin (LV) and irinotecan or 5-FU, LV and oxaliplatin. Methods: A total 14 patients (median age 56 years) with advanced colorectal cancer, all of them had progressed after oxaliplatin and irinotecan based combination chemotherapy, were enrolled in this study. Patients were treated with 2 hour infusion of irinotecan 150 mg/m 2 on day 1, plus bevacizumab 5 mg/kg iv infusion for 90 minute on day 2, intravenous (iv) injection of leucovorin 20 mg/m 2 followed by a bolus of 5-FU 400 mg/m 2 and then 22 hour continuous infusions of 600 mg/m 2 given on 2 consecutive days every 14 days. Results: The median cycles of chemotherapy were six (range 3 to 12). The response rate was 28.5%, one patient (7.1%) had a complete response, and three patients (21.4%) had a partial response. Eight patients (57.1%) had stable disease, and two patients (14.3%) progressed. The median time to progression was 3.9 months (95% confidence interval (CI) 2.0–8.7 months), and the median overall survival was 10.9 months (95% CI 9.6–12.1 months). Grade 3/4 neutropenia occurred in 5 patients, among them 2 patients developed neutropenic fever. Grade 3 hematuria and hematochezia occurred in one patient. Grade 2 proteinuria occurred in two patients. However, hypertension, bowel perforation or thromboembolic events were not occurred in total 90 cycles. Conclusions: Bevacizumab with FOLFIRI is well tolerated and improves survival in heavily treated advanced colorectal cancer patients. Further studies are needed to confirm these results. No significant financial relationships to disclose.
CD37−SMIPTM Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.
Authors: Rosa Lapalombella, Xiaobin B. Zhao, Laura Grosmaire, Jeffrey A. Ledbetter, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2006)
Integrating precision cancer medicine into healthcare—policy, practice, and research challenges
Authors: Gabrielle Bertier, Jian Carrot-Zhang, Vassilis Ragoussis, Yann Joly
Journal: Genome Medicine (2016)

Precision medicine (PM) can be defined as a predictive, preventive, personalized, and participatory healthcare service delivery model. Recent developments in molecular biology and information technology make PM a reality today through the use of massive amounts of genetic, 'omics', clinical, environmental, and lifestyle data. With cancer being one of the most prominent public health threats in developed countries, both the research community and governments have been investing significant time, money, and efforts in precision cancer medicine (PCM). Although PCM research is extremely promising, a number of hurdles still remain on the road to an optimal integration of standardized and evidence-based use of PCM in healthcare systems. Indeed, PCM raises a number of technical, organizational, ethical, legal, social, and economic challenges that have to be taken into account in the development of an appropriate health policy framework. Here, we highlight some of the more salient issues regarding the standards needed for integration of PCM into healthcare systems, and we identify fields where more research is needed before policy can be implemented. Key challenges include, but are not limited to, the creation of new standards for the collection, analysis, and sharing of samples and data from cancer patients, and the creation of new clinical trial designs with renewed endpoints. We believe that these issues need to be addressed as a matter of priority by public health policymakers in the coming years for a better integration of PCM into healthcare.
GW26-e3603 Cardiac Fibroblast Contributes to Myocardial Fibrosis in Mice With Diabetes Mellitus-Role of Cardiomyocyte-Fibroblast Interaction
Authors: Jia Song, Aibing Tao, Hao Wang, Weipeng Jiang, Jingxia An, Guohui Zhang, Tao Rui
Journal: Journal of the American College of Cardiology (2015)
Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial
Authors: M Larrayoz, M J J Rose-Zerilli, L Kadalayil, H Parker, S Blakemore, J Forster, Z Davis, A J Steele, A Collins, M Else, D Catovsky, D G Oscier, J C Strefford
Journal: Leukemia (2016)
David Oliver: Four riders of the NHS apocalypse
Authors: David Oliver
Journal: BMJ (2016)

The NHS faces an existential crisis. Last week, four news stories foretold its apocalypse. Think of them as the four horse riders from the Book of Revelation.1

On 11 October Chris Hopson, chief of NHS Providers, told the Commons health select committee that England’s 44 sustainability and transformation plans (STPs) seemed unrealistic and vastly overambitious, even to their authors. Drafted under excessive pressure, these plans were “at risk of blowing up.”2 Hopson’s earlier written evidence had warned of financial shortfalls and rising demand and costs, making even current service levels unsustainable.3

The plans …
Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma
Authors: Raynier Devillier, Diane Coso, Luca Castagna, Isabelle Brenot-Rossi, Antonella Anastasia, Arturo Chitit, Jean Marc Schiano, Armando Santoro, Christian Chabannon, Monica Balzarotti, Didier Blaise, Reda Bouabdallah
Journal: Blood (2011)
GW26-e3961 Correlation between the degree of plaque inflammation and adventitial perfusion in the carotid artery: a combined 18F-fluorodeoxyglucose positron-emission tomography and dynamic contrast-enhanced magnetic resonance imaging study
Authors: Yang Liu, Juan Wang, Changzai Liang, Yuerui Li, Hui Zhang, Hongbin Liu
Journal: Journal of the American College of Cardiology (2015)
Fate of disappeared hepatic metastasis after mFOLFOX6 plus bevacizumab therapy.
Authors: Hiroyuki Uetake, Toshiaki Ishikawa, Kenichi Sugihara
Journal: Journal of Clinical Oncology (2012)

e14127 Background: Neoadjuvant and conversion chemotherapy for liver limited metastasis from colorectal cancer (CRC) is a current topic. Minute liver metastasis sometimes disappears on preoperative imaging and intraoperative examination (including contrast enhanced intraoperative ultrasonography (CEIOUS)) after chemotherapy using highly effective regimen, such as FOLFOX or FOLFIRI with molecular targeted agent. We reported a high pathological complete response (CR) rate of resected liver metastasis from CRC after preoperative mFOLFOX6 plus bevacizumab (Bmab) therapy (AACR 2011, abstract #3218), but It is still unclear whether disappeared lesions after chemotherapy need to be removed. Methods: Out of 17 patients with liver limited metastasis from CRC treated with mFOLFOX6 plus Bmab therapy, 9 patients (52%) underwent liver resection after chemotherapy. In 6 of the 9 patients, one or more disappeared lesion(s) after the chemotherapy was not resected and followed up by enhanced CT once every 3 months. Follow up period was 9 to 33 months (22 months in median). Results: Before chemotherapy, 53 liver metastases were detected in the 6 patients. After chemotherapy, 29 (55%) lesions were not detected by preoperative CT or CEIOUS. All the 24 lesion, which were pointed out at the operation, were resected. By histological examination, no viable tumor cell was observed in 12 lesions (50%) among resected lesions. In follow up period, in situ recurrence occurred in 5 lesions (17%) in 4 patients. Three of the 4 patients underwent curative resection of re-detected liver metastases. Conclusions: It was reported that cancer cells remain over 80% of clinically disappeared lesion after conventional chemotherapy. In the present study, only 17% of disappeared lesion after mFOLFOX6 plus Bmab therapy caused in situ recurrence. With this result and a high pathological CR rate of the resected liver metastases after mFOLFOX6 plus Bmab therapy, it is speculated that complete resection for disappeared lesions after this chemotherapy is not always necessary.
The Face That Thinks
Authors: Jayshil J. Patel
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart Failure
Authors: Jacob P. Kelly, Christopher B. Granger
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Drop-out between the two liver resections of two-stage hepatectomy for multiple bilobar colorectal metastases: Patient selection or loss of chance?
Authors: Luca Vigano, Guido Torzilli, Matteo Maria Cimino, Katsunori Imai, Guido Costa, Fabio Procopio, Matteo Donadon, Denis Castaing, Rene Adam
Journal: Journal of Clinical Oncology (2015)

e14674 Background: Two-stage hepatectomy (TSH) is the present standard for multiple bilobar colorectal liver metastases (CLM). Its main drawback is the drop-out risk (25-40% of patients fail to complete the second hepatectomy because of disease progression). The study aimed to elucidate if drop-out is a patient selection (as usually considered) or a loss of chance. Methods: All the consecutive patients scheduled for a TSH at the Paul Brousse Hospital between 2000 and 2012 were considered. Patients with extra-hepatic distant metastases or intraoperative radiofrequency ablation were excluded. TSH patients were matched 1:1 with patients affected by multiple bilobar CLM receiving a one-stage ultrasound-guided hepatectomy (OSH) at the Humanitas Research Hospital in the same period. Matching criteria were: primary tumor N status; timing of CLM diagnosis; CLM number and distribution into the liver. Results: Sixty-three pairs of patients were analyzed. Demographic and tumor characteristics were similar between groups (a median of 7 CLM), as well as chemotherapy regimens and duration. Drop-out rate of TSH was 38.1% (vs. 0% of OSH). In an intention-to-treat perspective, the two groups had similar R0 resection rate (19.0% OSH vs. 15.9% TSH). After a median follow-up of 35.5 months, OSH and completed TSH had similar five-year survival rates (from CLM diagnosis 49.8% vs. 49.7%, from liver resection 36.1% vs. 44.3%, p = n.s.), largely superior to drop-out patients (10% three-year survival, p < 0.001). OSH and completed TSH had similar recurrence-free survival (at three years 21.7% vs. 20.5%) and recurrence sites. At multivariate analysis, the completion of resection (drop-out vs. OSH/completed TSH) was the only independent prognostic factor (p = 0.003). Conclusions: The drop-out of TSH seems to be a loss of chance rather than a patient selection. “Unselected” OSH patients had the same outcomes of selected patients who completed the TSH. A complete resection is the main determinant of prognosis in patients with multiple bilobar CLM.
Immunotherapy, phase I study of immunotherapy with carcinoembryonic antigen peptide -pulsed, autologous human cultured dendritic cells in patients with advanced non-small cell lung cancer
Authors: B. Han, Z. Huan, F. Xiaohong, L. Rong, F. Guangli, J. Luoluo, C. Tianqing, Z. Wei, S. Jianzhong
Journal: Journal of Clinical Oncology (2006)

12517 Background: To study toxicity tolerance and dose-effect relationship of carcinoembryuonic antigen peptide-pulsed dendritic cells in patients with advanced lung cancer. Methods: cells preparations enriched for autologous DCs were generated from the patients plastic adherent peripheral blood mononuclear cells in media supplemented with granulocyte macrophage colony -stimulating factor and interleukin-4. 37C 0 , 5%CO 2 culture for 7–10. The DCs were loaded with carcinoembryonic antigen(CEA) in day 7, Groups of three to six patients received four weekly or biweekly i.v. infusions of the CAP-1-loaded DC in escalating dose levels of 1 × 10 6 , 1 × 10 7 , and 1 × 10 8 cells/dose. Patients with lung cancer received iv injections DCs. There were no toxicities directly referable to the treatments. Results: Total 22 patients with lung cancer received DCs immunotherapy. DCs infusion were 2.5×10 6 -9.6×10 7 ,means 15.03×10 6 . The early clinical trials suggest that vaccination with CEA vaccines is safe, producing few side-effects, and can lead to CEA-specific immunity. Conclusions: We conclude that it is feasible and safe to generate and administer large numbers of DCs loaded with CEA peptide to patients with lung cancer. No significant financial relationships to disclose.
A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI
Authors: Yoo-Hong Min, Hyeoung Joon Kim, Kyoo Hyung Lee, Sung-Soo Yoon, Jae Hoon Lee, Hee-Sook Park, Jin Seok Kim, Ho Young Kim, Hyeok Shim, Chu-Myong Seong, Chul Soo Kim, Jooseop Chung, Myung Soo Hyun, Deog-Yeon Jo, Chul Won Jung, Sang Kyun Sohn, Hwi-Joong Yoon, Byung Soo Kim, Young-Don Joo, Chi-Young Park, June-Won Cheong
Journal: Blood (2008)
Severe Impairment of Dendritic Cell Allostimulatory Activity by Sendai Virus Vectors Is Overcome by Matrix Protein Gene Deletion.
Authors: Sorin Armeanu, Michael Bitzer, Irina Smirnov, Sascha Bossow, Silke Appel, Guy Ungerechts, Christian Bernloehr, Lothar Kanz, Wolfgang J. Neubert, Ulrich M. Lauert, Peter Brossart
Journal: Blood (2005)
Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD).
Authors: R. Lowsky, K. Heydari, B. Sahaf, J. Shizuru, G. Laport, L. Johnston, K. Stockerl-Goldstein, S. Arai, D. Miklos, K. Blume, L. Herzenberg, R. Negrin, S. Strober
Journal: Blood (2005)
The computer will assess you now
Authors: Stephen Armstrong
Journal: BMJ (2016)

Stephen Armstrong reports on work to develop machines that can diagnose conditions faster and more accurately than people

Can a game of space invaders defeat the largest cause of sight loss in the developed world? Research at the heart of a controversial deal between Google’s artificial intelligence (AI) company DeepMind and Moorfields Eye Hospital aims to find out.

DeepMind, a UK based company founded in 2010, recently signed a series of deals with NHS hospitals to develop diagnostic tools for a series of common conditions, including age related macular degeneration with Moorfields,1 head and neck cancer with University College London Hospitals (UCLH),2 and acute kidney injury with the Royal Free.3

“I approached DeepMind’s founder Mustafa Suleyman after reading an interview with him in Wired, 4” says Pearse Keane, a consultant ophthalmologist at Moorfields Eye Hospital, who specialises in conditions of the retina, including age related macular degeneration.

Over 600 000 people in the UK have age related macular degeneration, and 200 people are diagnosed with the condition every day.5 Over the past 10 years, optical coherence tomography (OCT) has revolutionised diagnosis.6 The technique uses light waves to take cross sectional pictures of the retina. Several high street opticians already offer OCT scans in the UK, but the problem, according to Keane, “is that they don’t always have the necessary training to read the scans.” He says that high street opticians are referring large numbers of people with false positive results for urgent NHS assessment. “We’re struggling to deal with the workload, and it means patients who do have macular degeneration may not be seen in time while those who don’t spend time worrying.”

DeepMind’s machine learning seemed to offer a solution—in February 2015 the company published a paper in Nature showing the results of an …
GW26-e0193 The Effect of Coronary Artery Ligation at Different Sites on Sympathetic Remodeling Post Myocardial Infarction in Rats
Authors: Jian Chen, Mao Liu, Fei Wang, Wenyi Tang, Zhijuan Zhou, Guangyi Tan, Chunli Han, Wei Wu
Journal: Journal of the American College of Cardiology (2015)
Use of nondebulkability score to predict residual disease and surgical morbidity in ovarian cancer.
Authors: C. J. Stashwick, M. A. Spillman, K. Behbakht, S. A. Davidson, M. G. Kelly
Journal: Journal of Clinical Oncology (2010)

e15508 Background: Neoadjuvant chemotherapy, compared to primary surgery, may be associated with less morbidity and comparable survival in a subset of ovarian cancer patients. There is no paradigm for selecting primary surgery versus neoadjuvant chemotherapy. The optimal duration of chemotherapy prior to interval surgery is also unknown. The purpose of this study is to develop a non-debulkability score (NDS). Methods: We identified 102 consecutive institutional cases of women with stage IIIC-IV ovarian cancer undergoing surgical management during the past 5 years. CT scans were reviewed for pleural effusions, ascites, studding, diaphragmatic, mesenteric, peri-splenic (PS), peri-hepatic and peri-colonic disease and retroperitoneal lymphadenopathy. Multivariate assessment of preoperative factors was carried out using backward stepwise regression (sig = p < 0.05). Results: 77 patients underwent initial surgery and 25 patients were treated with chemotherapy followed by surgery. 71 of 102 (70%) patients were optimally cytoreduced (residual disease \h = 1 cm). 27% of patients had microscopic residual disease (RD), 44% had between 0-1 cm, 5% had between 1-2 cm and 24% of patients had > 2 cm of RD. High CA-125 level (p \h 0.03), low albumin (p \h 0.03), high platelets (p \h 0.05) and para-aortic lymphadenopathy (PaL) (p \h 0.005) were predictive of RD. Low albumin (p \h 0.03), PS (p \h 0.001) and PaL (p \h 0.04) were predictive of a major surgical complication (COMP = organ injury, reoperation, death). NDS (0-70) was determined by adding 10 points each for CA-125 level > 500, platelets > 500K, PS and 20 points each for albumin \h 2.7, PaL. Mean NDS of patients who had successful surgery (optimal cytoreduction and no COMP) was significantly lower compared to patients who had unsuccessful surgery (suboptimal cytoreduction or COMP) (11 ± 2 versus 37 ± 3; p \h 0.0001). The sensitivity, specificity, PPV and NPV of NDS were 85%, 88%, 93% and 73%; respectively. Conclusions: CA-125, albumin, platelets, PS and PaL predicted successful surgery. NDS may be useful in selecting initial treatment in advanced ovarian cancer patients. For patients receiving neoadjuvant chemotherapy, NDS might further help guide optimal timing of interval surgery. No significant financial relationships to disclose.
Leucocyte telomere length, genetic variants at the<i>TERT</i>gene region and risk of pancreatic cancer
Authors: Ying Bao, Jennifer Prescott, Chen Yuan, Mingfeng Zhang, Peter Kraft, Ana Babic, Vicente Morales-Oyarvide, Zhi Rong Qian, Julie E Buring, Barbara B Cochrane, J Michael Gaziano, Edward L Giovannucci, JoAnn E Manson, Kimmie Ng, Shuji Ogino, Thomas E Rohan, Howard D Sesso, Meir J Stampfer, Charles S Fuchs, Immaculata De Vivo, Laufey T Amundadottir, Brian M Wolpin
Journal: Gut (2016)

<h3>Objective</h3> Telomere shortening occurs as an early event in pancreatic tumorigenesis, and genetic variants at the telomerase reverse transcriptase (<i>TERT</i>) gene region have been associated with pancreatic cancer risk. However, it is unknown whether prediagnostic leucocyte telomere length is associated with subsequent risk of pancreatic cancer. <h3>Design</h3> We measured prediagnostic leucocyte telomere length in 386 pancreatic cancer cases and 896 matched controls from five prospective US cohorts. ORs and 95% CIs were calculated using conditional logistic regression. Matching factors included year of birth, cohort (which also matches on sex), smoking status, fasting status and month/year of blood collection. We additionally examined single-nucleotide polymorphisms (SNPs) at the <i>TERT</i> region in relation to pancreatic cancer risk and leucocyte telomere length using logistic and linear regression, respectively. <h3>Results</h3> Shorter prediagnostic leucocyte telomere length was associated with higher risk of pancreatic cancer (comparing extreme quintiles of telomere length, OR 1.72; 95% CI 1.07 to 2.78; p<sub>trend</sub>=0.048). Results remained unchanged after adjustment for diabetes, body mass index and physical activity. Three SNPs at <i>TERT</i> (linkage disequilibrium r<sup>2</sup>&lt;0.25) were associated with pancreatic cancer risk, including rs401681 (per minor allele OR 1.33; 95% CI 1.12 to 1.59; p=0.002), rs2736100 (per minor allele OR 1.36; 95% CI 1.13 to 1.63; p=0.001) and rs2736098 (per minor allele OR 0.75; 95% CI 0.63 to 0.90; p=0.002). The minor allele for rs401681 was associated with shorter telomere length (p=0.023). <h3>Conclusions</h3> Prediagnostic leucocyte telomere length and genetic variants at the <i>TERT</i> gene region were associated with risk of pancreatic cancer.
Pharmacological Blockade of NF-kB Targets Both Imatinib-Sensitive or -Resistant Chronic Myeloid Leukemia Cells for Cell Death.
Authors: Véronique Imbert, Nadia Lounnas, Catherine Frelin, Nadège Gonthier, Emmanuel Griessinger, Nicolas Sirvent, Michael Hummelberger, Jil-Patrice Cassuto, François-Xavier Mahon, Jean-François Michiels, Philippe Rousselot, Michel Dreano, Jean-François Peyron
Journal: Blood (2006)